<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34897701</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1552-4604</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>62</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical pharmacology</Title>
          <ISOAbbreviation>J Clin Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.</ArticleTitle>
        <Pagination>
          <StartPage>812</StartPage>
          <EndPage>822</EndPage>
          <MedlinePgn>812-822</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jcph.2013</ELocationID>
        <Abstract>
          <AbstractText>Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study investigated the impact of hepatic impairment (HI) on acalabrutinib pharmacokinetics (PK) and safety at a single 50-mg dose in fasted subjects. This study was divided into 2 parts: study 1, an open-label, parallel-group study in Child-Pugh class A or B subjects and healthy subjects; and study 2, an open-label, parallel-group study in Child-Pugh class C subjects and healthy subjects. Baseline characteristics and safety profiles were similar across groups. Acalabrutinib exposure (area under the plasma concentration-time curve) increased slightly (1.90- and 1.48-fold) in subjects with mild (Child-Pugh class A) and moderate (Child-Pugh class B) hepatic impairment compared with healthy subjects. In severe hepatic impairment (Child-Pugh class C), acalabrutinib exposure (area under the plasma concentration-time curve and maximum plasma concentration) increased ≈5.0- and 3.6-fold, respectively. Results were consistent across total and unbound exposures. Severe hepatic impairment did not impact total/unbound metabolite (ACP-5862) exposures; the metabolite-to-parent ratio decreased to 0.6 to 0.8 (vs 3.1-3.6 in healthy subjects). In summary, single oral dose of 50-mg acalabrutinib was safe and well tolerated in subjects with mild, moderate, and severe hepatic impairment and in healthy control subjects. In subjects with severe hepatic impairment, mean acalabrutinib exposure increased by up to 5-fold and should be avoided. Acalabrutinib does not require dose adjustment in patients with mild or moderate hepatic impairment.</AbstractText>
          <CopyrightInformation>© 2021 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Quantitative Clinical Pharmacology, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Izumi</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Development, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nguyen</LastName>
            <ForeName>Helen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Development, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kwan</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Development, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuo</LastName>
            <ForeName>Howard</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Quantitative Clinical Pharmacology, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Madere</LastName>
            <ForeName>Jeannine</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Development, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Slatter</LastName>
            <ForeName>J Greg</ForeName>
            <Initials>JG</Initials>
            <AffiliationInfo>
              <Affiliation>Quantitative Clinical Pharmacology, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Podoll</LastName>
            <ForeName>Terry</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Quantitative Clinical Pharmacology, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vishwanathan</LastName>
            <ForeName>Karthick</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-6555-8131</Identifier>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marbury</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Orlando Clinical Research Center, Orlando, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>William</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Alliance for Multispecialty Research, University of Tennessee Medical Center, Knoxville, Tennessee, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Preston</LastName>
            <ForeName>Richard A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Pharmacology, Department of Medicine, The Peggy and Harold Katz Family Drug Discovery Center, University of Miami Clinical and Translational Science Institutes (CTSI), University of Miami, Miami, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharma</LastName>
            <ForeName>Shringi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Quantitative Clinical Pharmacology, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ware</LastName>
            <ForeName>Joseph A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Quantitative Clinical Pharmacology, AstraZeneca, South San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Clin Pharmacol</MedlineTA>
        <NlmUniqueID>0366372</NlmUniqueID>
        <ISSNLinking>0091-2700</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008107" MajorTopicYN="Y">Liver Diseases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">ACP-5862</Keyword>
        <Keyword MajorTopicYN="Y">acalabrutinib</Keyword>
        <Keyword MajorTopicYN="Y">hepatic impairment</Keyword>
        <Keyword MajorTopicYN="Y">pharmacokinetics</Keyword>
        <Keyword MajorTopicYN="Y">phase 1 study</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>13</Hour>
          <Minute>37</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34897701</ArticleId>
        <ArticleId IdType="doi">10.1002/jcph.2013</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016. https://seer.cancer.gov/csr/1975_2016/. Published 2019. Accessed September 14, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(suppl 6):vi50-54.</Citation>
        </Reference>
        <Reference>
          <Citation>Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol. 2011;29(5):544-550.</Citation>
        </Reference>
        <Reference>
          <Citation>Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(5):589-597.</Citation>
        </Reference>
        <Reference>
          <Citation>Zelenetz AD, Gordon LI, Wierda WG, et al. Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw. 2014;12(6):916-946.</Citation>
        </Reference>
        <Reference>
          <Citation>Mohamed AJ, Yu L, Bäckesjö CM, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228(1):58-73.</Citation>
        </Reference>
        <Reference>
          <Citation>Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal. 2010;22(8):1175-1184.</Citation>
        </Reference>
        <Reference>
          <Citation>Vihinen M, Mattsson PT, Smith CI. Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA). Front Biosci. 2000;5:D917-D928.</Citation>
        </Reference>
        <Reference>
          <Citation>Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol. 2012;31(2):119-132.</Citation>
        </Reference>
        <Reference>
          <Citation>Herman SEM, Montraveta A, Niemann CU, et al. The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(11):2831-2841.</Citation>
        </Reference>
        <Reference>
          <Citation>Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363(2):240-252.</Citation>
        </Reference>
        <Reference>
          <Citation>Podoll T, Pearson PG, Evarts J, et al. Bioavailability, biotransformation, and excretion of the covalent Bruton tyrosine kinase inhibitor acalabrutinib in rats, dogs, and humans. Drug Metab Dispos. 2019;47(2):145-154.</Citation>
        </Reference>
        <Reference>
          <Citation>Calquence [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Kaptein A, Podoll T, de Bruin G, et al. Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity [abstract]. Cancer Res. 2019;79(13 suppl):2194.</Citation>
        </Reference>
        <Reference>
          <Citation>Kawasaki S, Sugiyama Y, Iga T, et al. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. Clin Pharmacol Ther. 1988;44(2):217-224.</Citation>
        </Reference>
        <Reference>
          <Citation>US Food and Drug Administration. Guidance for industry pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing-and. Published 2003. Accessed September 14, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function_en.pdf. Accessed September 14, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Edlund H, Lee SK, Andrew MA, Slatter JG, Aksenov S, Al-Huniti N. Population pharmacokinetics of the BTK inhibitor acalabrutinib and its active metabolite in healthy volunteers and patients with B-cell malignancies. Clin Pharmacokinet. 2019;58(5):659-672.</Citation>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323-332.</Citation>
        </Reference>
        <Reference>
          <Citation>Pepin XJH, Moir AJ, Mann JC, et al. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices. Eur J Pharm Biopharm. 2019;142:435-448.</Citation>
        </Reference>
        <Reference>
          <Citation>Izumi R, Pearson PG, Hamdy A, et al. CYP3A-mediated drug interaction profile of Bruton tyrosine kinase inhibitor, acalabrutinib [abstract]. Blood. 2017;130(suppl 1):4996.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659-667.</Citation>
        </Reference>
        <Reference>
          <Citation>de Jong J, Skee D, Hellemans P, et al. Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment. Leuk Lymphoma. 2017;58(1):185-194.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9(12):929-939.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou D, Podoll T, Xu Y, et al. Evaluation of the drug-drug interaction potential of acalabrutinib and its active metabolite, ACP-5862, using a physiologically-based pharmacokinetic modeling approach. CPT Pharmacometrics Syst Pharmacol. 2019;8(7):489-499.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
